Search for a trial

A PHASE II, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF CARBOPLATIN/PACLITAXEL AND CARBOPLATIN/PACLITAXEL/BEVACIZUMAB WITH AND WITHOUT GDC-0941 IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER.

PRIMARY OBJECTIVES Part I - To evaluate the efficacy (as measured by PFS) of GDC-0941 340 mg +carboplatin * paclitaxel (Arm A) versus carboplatin * paclitaxel (Arm B) in all patients with squamous NSCLC -To evaluate the efficacy (as measured by PFS…

A randomized, double-blinded, placebo-controlled, single centre, phase I study of the safety of escalating single intravenous doses of NI-0801 in healthy volunteers.

To assess the safety and tolerability of escalating single IV doses of NI-0801.To determine the pharmacokinetics and pharmacodynamics parameters of escalating single IV doses of NI-0801.

Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A

The primary objective is to evaluate the effect of a once-a-weekprophylaxis regimen with BAY 79-4980 on the protection from all bleeds compared to a three times-per-week prophylaxis regimen with rFVIII-FSWFI.

A multi-center, randomized, vehicle-contolled study to assess the efficacy and safety of adalimumab in combination with topical treatment (calcipotriol/betamethasone) in subjects with moderate to severe psoriasis and insufficient response to classic systemic treatment.

The objective of this study is to assess the efficacy and safety of adalimumab in combination with a topical treatment for the treatment of patients with moderate to severe chronic plaque psoriasis.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy.

The primary objectives of this study are:• To determine whether ART-123, when administered to subjects with infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality.• To determine the safety of ART-123 in this…

A randomized, parallel-group clinical pharmacology study to assess the pharmacokinetics and pharmacodynamics of Tysabri® in healthy volunteers

The purpose of this study is to investigate how quickly and to what extent different doses of EU­approved Tysabri® are absorbed and eliminated from the body (this is called pharmacokinetics) and how the body responds to different doses of Tysabri (…

A randomized, double-blind, placebo-controlled multiple ascending dose study to assess safety, pharmacokinetics and pharmacodynamics of oral HTL18318 in healthy young adult and elderly subjects.

1. To evaluate the safety and tolerability of ascending multiple oral doses of HTL18318 in healthy adult male and female subjects.2. To evaluate the pharmacokinetics of ascending multiple oral doses of HTL18318 in healthy adult male and female…

A randomized, double-blind, placebo-controlled, parallel-group, phase 2 study to evaluate the safety and efficacy of CT1812 in subjects with mild to moderate Alzheimer's disease

The purpose of this study is to evaluate the safety and efficacy of two doses of the study drug CT1812 per day for six months in subjects with mild to moderate Alzheimer's disease. CT1812 will be compared with a placebo. A placebo is a product…

Pharmacogenetics Use For Further treatment Improvement in childreN

To assess whether ADRB2 genotype-guided asthma treatment in children with persistend athma symptoms despite ICS treatment leads to better asthma control compared to non-genotype-guided asthma treatment.